NCI-H929/NCI-H929/NCI-H929/人骨髓

NCI-H929/NCI-H929细胞系/NCI-H929细胞株/NCI-H929人骨髓瘤细胞

Cell line name NCI-H929

Synonyms NCI H929; NCIH929; H929; H-929

Accession CVCL_1600

Resource Identification Initiative To cite this cell line use: NCI-H929 (RRID:CVCL_1600)

Comments Group: Patented cell line.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MYC genetic alteration cell panel (ATCC TCP-1035).

Part of: RAS genetic alteration cell panel (ATCC TCP-1031).

Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9068.

Population: Caucasian.

Characteristics: Produces IgA kappa.

Doubling time: ~50 hours (Patent=US4892829; PubMed=2423157); ~70 hours (DSMZ=ACC-163).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.

PubMed=16956823

Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L., Moreau P., Amiot M., Pellat-Deceunynck C.

The phenotype of normal, reactive and malignant plasma cells Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.

Haematologica 91:1234-1240(2006)

 

PubMed=17171682; DOI=10.1002/gcc.20404

Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A.

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Genes Chromosomes Cancer 46:226-238(2007)

 

PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003; PMCID=PMC2083698

Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J., Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T., Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C., Brents L.A., Kumar S.K., Greipp P.R., Dispenzieri A., Bryant B., Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M., Stewart A.K., Carpten J.D., Bergsagel P.L.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Cancer Cell 12:131-144(2007)

 

PubMed=18647998; DOI=10.1093/jncimonographs/lgn011; PMCID=PMC2737184

Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.

Characterization of MYC translocations in multiple myeloma cell lines.

J. Natl. Cancer Inst. Monogr. 39:25-31(2008)

 

PubMed=18700954; DOI=10.1186/1755-8794-1-37; PMCID=PMC2531129

Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A., Fabris S., Lambertenghi-Deliliers G., Neri A.

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

BMC Med. Genomics 1:37.1-37.9(2008)

 

PubMed=19306352; DOI=10.1002/gcc.20660

Lionetti M., Agnelli L., Mosca L., Fabris S., Andronache A., Todoerti K., Ronchetti D., Lambertenghi-Deliliers G., Neri A.

Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.

Genes Chromosomes Cancer 48:521-531(2009)

 

PubMed=21173094; DOI=10.3324/haematol.2010.033456; PMCID=PMC3069235

Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D., Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M., Pellat-Deceunynck C.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Haematologica 96:574-582(2011)